Connect with us

Technology

Clarivate Announces 15th Annual Pharmavision India Conference Agenda

Published

on

Industry leaders to discuss AI in healthcare, cell and gene therapy, market access and more at premier life sciences event

LONDON, Sept. 18, 2024 /PRNewswire/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 15th annual Clarivate Pharmavision India conference. The 15th edition of Pharmavision India reinforces the industry’s dedication to patient welfare, highlighting how collective efforts and innovative strategies have transformed the healthcare ecosystem. With a focus on improving patient outcomes and building resilience, the two-day event will take place in Ahmedabad and Hyderabad on September 25-26, 2024.

In a country with billions of people, addressing challenges such as healthcare affordability and access is crucial. Organizations must adopt effective, patient-centric approaches across diverse functions to ensure return on investment and a competitive advantage. As the healthcare landscape evolves, balancing these priorities is essential for sustainable growth and better patient outcomes. Pharmavision India 2024 will provide attendees with the opportunity to tackle the industry’s most urgent challenges in life sciences and healthcare.

Ramandeep Singh, Vice President, Life Sciences and Healthcare, India, Clarivate, said: “Since its inception in 2010, Pharmavision India has been a crucial platform for the pharmaceutical, biotech, and healthcare sectors. It enables industry leaders to align, strategize, and drive growth in a competitive landscape. This event is pivotal for fostering innovation across R&D, generics, biosimilars, and healthcare manufacturing. Our expertise and leadership position us uniquely to lead this conference, advancing industry standards and creating collaboration opportunities.”

Henry Levy, President, Life Sciences and Healthcare, Clarivate, added: “At Clarivate, our mission is to foster collaboration across life sciences and healthcare industries, driving strategies that enhance patient outcomes and sustainable growth. We are proud to bring together industry leaders to tackle the vital challenge of integrating patient-centric innovation in today’s evolving market through impactful forums such as Clarivate Pharmavision India.”

This year’s agenda features insights and perspectives from industry leaders and analysts, with sessions focused on innovative R&D, generics, biosimilars and healthcare manufacturing. Noteworthy sessions include:

Indian Pharma: Generics versus innovation – finding the balance for success, by Dr. Keyur Parekh, President, Corporate Strategy, Zydus Lifesciences LimitedThe role of AI and big data in healthcare: Transformative impacts and future prospects, by Mr. Anirban Roy Chowdhury, Senior General Manager, Amneal PharmaceuticalsCell and gene therapy: Addressing key barriers for successful integration into clinical practice in the Indian context, by Dr. Tulip Nuval, Head of Business Excellence, Intas Pharmaceuticals Limited Cell and gene therapy: Addressing key barriers for successful integration into clinical practice in the Indian context, by Mr. Rebu Ninan, Head of Commercial & Market Access, Immuneel Therapeutics Private LimitedPatients and the LMIC story: How Indian companies drive affordability in the global scenario, by Dr. Rahul Kapur, Head – Medical Affairs (EM) and COE, Biocon Biologics Limited Creating value for patients and stakeholders, by Mr. Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories 

Pharmavision India takes place on Wednesday, September 25, 2024, at the Hyatt Ahmedabad, and Thursday, September 26, 2024, at the Taj Deccan, Hyderabad. Register to attend and learn more on this premier event, here.

Connect with Clarivate Life Sciences and Healthcare. Join the conversation and mention Clarivate and Pharmavision on X and LinkedIn.  #Pharmavision #PatientCare #Biopharma #ThinkForward

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact:
Catherine Daniel
Director External Communications, Life Sciences & Healthcare
newsroom@clarivate.com 

SOURCE Clarivate Plc

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 20, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

View original content:https://www.prnewswire.com/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947422.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Allooloo Tops 100M Capital Markets AI Agent Traffic a Month

Published

on

By

Agentic datasets on every listed company in 34 countries: sourced, dated and signed.

VANCOUVER, BC and LONDON, Nov. 21, 2026 /PRNewswire/ — Allooloo Technologies Corp. (Allooloo), maker of agentic datasets for capital markets artificial intelligence (AI) agents, today reported 100M AI agent traffic a month. That is 39 calls a second, 3.4 million a day, across getissuer.ai and Issuerwire.ai, running on 24 Microsoft Azure hyperscale locations globally with always-on Amazon Web Services (AWS) redundancy.

The Data Readiness Gap

Investment banks are not short of AI models. They are short of data an AI agent can use. In a 2026 Teradata study, 77% of technology leaders said 20% or less of their enterprise data is ready for AI agents. Banks are closing that gap on the data they hold, with one governed way in and the source, the date and the owner on every record.

The data a bank does not hold is the other half. An AI agent working on a security needs the issuer, its disclosures and whether it may be ordered, in every market the bank trades. Allooloo delivers that half agent-ready: 41.9K listed companies in 34 countries, a source and a date on every field, and a signed receipt for every read, over Model Context Protocol (MCP).

Two Products

Know Your Product (KYP) is the duty to know a security before it is recommended or sold. Allooloo KYP, at getissuer.ai, answers it for the AI agent: who the issuer is, whether it may be ordered, and who it is for. It covers 41.9K listed companies on 79 exchanges in 34 countries.

Issuerwire.ai is the dated disclosure wire: 3.1 million dated disclosures across 34 countries, each with its source.

Who it matters to:

Investment bank or dealer: its AI agents can show where each fact came from.The issuer: every AI agent reads the same answer about it.Compliance: a signed receipt for every cleared read.

A Signed Receipt for Every Read

Every cleared read on Allooloo leaves a signed receipt, the Record of Cleared Orders (RCO): what was read, when, and under which market’s rules.

Each Market in Its Own Country

Each market is kept in its own country or region, across 24 Microsoft Azure regions, on one MCP server per market. A second copy of every market is made each night on AWS and locked against deletion for 365 days. Allooloo is a Microsoft AI Cloud Partner.

Around the Clock

The products are made around the clock by Allooloo’s own team and AI agents, on the Allooloo Algo. AI agents call them around the clock and pay per call, with no seat and no licence.

“Today we are announcing a milestone: 100M AI agent traffic a month,” said Matthew Keddy, Chief Executive Officer of Allooloo Technologies Corp. “These are the AI agents of capital markets participants, and they want crisp data, five years deep, on 41.9K listed companies across 79 exchanges: sourced, dated and signed. Gain the edge with us.”

In Session and Enterprise Grade

Allooloo is sold two ways. In session, an AI agent calls Allooloo mid-task and pays as it goes (PayGo) on x402, the open payment standard for AI agents, with no seat and no licence. At enterprise grade, a firm licenses the datasets to design, build and run its own AI agents.

About Allooloo Technologies Corp.

Allooloo Technologies Corp. makes agentic capital markets data products for the AI agents of banks, dealers and issuers. Its products, getissuer.ai and Issuerwire.ai, cover 41.9K listed companies on 79 exchanges in 34 countries, kept across 24 Microsoft Azure regions with on-the-fly redundancy on Amazon Web Services (AWS). The result is always-on agentic datasets: in session for AI lab users, and enterprise grade for customers who design, build and run their own AI agents. Allooloo is headquartered in Vancouver, Canada. Please visit: allooloo.ai 

Contact: Matthew Keddy, CEO. mk@allooloo.ai +1 647 237 7744

View original content:https://www.prnewswire.com/apac/news-releases/allooloo-tops-100m-capital-markets-ai-agent-traffic-a-month-302947427.html

SOURCE Allooloo Technologies Corp.

Continue Reading

Technology

Ziehm-Orthoscan Announces Executive Leadership Transition Following 18 Years of Significant Growth

Published

on

By

Ziehm-Orthoscan Announces CEO Transition and Executive Leadership Appointments

SCOTTSDALE, Ariz., Nov. 20, 2026 /PRNewswire-PRWeb/ — Ziehm-Orthoscan Inc., the leader in mobile C-arm imaging solutions, today announced an executive leadership transition as President and Chief Executive Officer Nelson Mendes prepares to step down on December 31, 2026, following 18 years of distinguished leadership.

Effective January 1, 2027, Travis Prikryl will assume the role of Chief Executive Officer, and Hogie Saunders will be appointed Chief Operating Officer. Both executives will also serve as Managing Directors of Ziehm-Orthoscan Inc.

Under Mendes’ leadership, Ziehm-Orthoscan experienced extraordinary growth and transformation, evolving from a small U.S. operation into a major contributor to the company’s global business. Since 2009, U.S. operations have grown from approximately six employees to nearly 200, reflecting Ziehm-Orthoscan’s significant expansion and continued investment. This growth includes the establishment of a new headquarters and production facility in Scottsdale, Arizona, which serves as the global center for the development and manufacturing of all Orthoscan mini C-arm systems.

A significant milestone in this transformation was the acquisition and integration of Orthoscan in 2015, bringing together Ziehm’s full-size mobile C-arm technology and Orthoscan’s mini C-arm expertise. This strategic expansion established a comprehensive mobile imaging portfolio, strengthened the company’s competitive position, and accelerated its growth throughout the U.S. healthcare market.

Throughout his tenure, Mendes championed innovation, operational excellence, and customer relationships, helping establish Ziehm-Orthoscan as a trusted imaging partner to healthcare institutions nationwide.

To ensure a seamless transition, Mendes will remain with the company as a full-time strategic advisor through March 31, 2027, followed by a part-time consulting role supporting the organization’s continued development.

The appointments of Travis Prikryl and Hogie Saunders represent the next chapter in Ziehm-Orthoscan’s long-term growth strategy. Together with the company’s experienced management team, they will focus on advancing imaging innovation, strengthening customer partnerships, expanding market opportunities, and building on the strong foundation established over the past 18 years.

Ziehm-Orthoscan extends its sincere appreciation to Nelson Mendes for his exceptional leadership and contributions while expressing full confidence in the incoming executive team to guide the organization into its next phase of growth and success.

About Ziehm-Orthoscan

Ziehm-Orthoscan is the leader of innovative mobile imaging solutions, combining Ziehm’s expertise in full-size mobile C-arms with Orthoscan’s specialized mini C-arm technology. The company is committed to advancing medical imaging through innovation, exceptional service, and solutions designed to meet the evolving needs of healthcare professionals.

Media Contact

Rich Shaul, Vice President Marketing, Ziehm-Orthoscan, Inc., 1 4805038010, marketing@ziehm-orthoscan.com, https://ziehm-orthoscan.com/

View original content to download multimedia:https://www.prweb.com/releases/ziehm-orthoscan-announces-executive-leadership-transition-following-18-years-of-significant-growth-302946604.html

SOURCE Ziehm-Orthoscan, Inc.

Continue Reading

Trending